Bioequivalence of Lamnet (Lamotrigine)100mg Tablet With the Reference Product Lamictal 100mg (Lamotrigine) Tablet Under Fasting Conditions

NCT04938856 | Completed Phase 1

• 1 other identifier: CB-026-LAM-2018/Protocol/2.0
• Study Type: interventional
• Target: 26
• Locations: 1 country
• Sites: 1

Brief Summary

Single oral administrations of study drug (Lamnet and Lamictal) in two periods separated by a washout period of 14 days. The washout period will be calculated from day of dosing (Day 2) to at least 14 days post dose in each period.

Conditions

Bioequivalence

Keywords

Bioequivalence Study; Healthy Volunteers; Pakistani Population; Safety

Outcome Measures

Primary Outcomes (3)

• Cmax

  maximum plasma concentration of Lamotrigine

  0-120 hours post dose

• AUC

  Area Under the Plasma Drug Concentration versus Time curve

  0 to 120 hours post dose

• Tmax

  Time required for maximum plasma drug concentration

  0-120 hours post dose

Secondary Outcomes (3)

• Blood Pressure monitoring

  0-120 hours post dose

• Body temperature measurement

  0-120 hours post dose

• Heart rate measurement

  0-120 hours post dose

Study Arms (2)

Test Group

EXPERIMENTAL

Oral administration of Lamnet (100mg) Tablet after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point.

Drug: Lamotrigine tablet

Reference Group

ACTIVE COMPARATOR

Oral administration of Lamictal (100mg) Tablet after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point.

Drug: Lamotrigine tablet

Interventions

Lamotrigine tablet DRUG

Lamotrigine 100 mg immediate release Tablet

Also known as: Test Group (Lamnet 100 mg), Reference Group (Lamictal 100 mg)

Reference Group; Test Group

Eligibility Criteria

• Age: 18 Years - 55 Years
• Gender Eligibility Details: Pakistani Population
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male volunteers aged 18 to 55 years inclusive.
• Subjects with a body mass index from 18.5 to 30 kg/m2 (both inclusive).
• Subjects who are healthy as determined by routine physical examination, including vital sign monitoring (i.e., blood pressure, heart rate and temperature), ECG monitoring and laboratory analysis (ie, hematology, blood biochemistry, and urinalysis)and viral serology as determined by the investigator.
• Tested negative for COVID-19 (through COVID-19 antibody testing).
• Subjects should have negative urine test for drugs of abuse (morphine, cannabinoids will be tested) and alcohol breath analysis at screening and prior to each check-in.
• Subjects will be able to, understand and sign the Informed Consent Form for Medical Screening during their screening visit and Participation Informed Consent Form on study check-In day.
• Subject agreed not to use special diet including fasting, high protein diet within the next 4 weeks.
• Subject agreed not to consume Alcohol, cigarette, gutka, caffeine or related xanthines containing foods or beverages (e.g. tea, coffee, cola drinks, chocolates, cocoa) etc and poppy seeds (khash khash) within 48 hours prior to drug administration.
• Subject agreed not to intake prescription drugs within 14 days or 5 half-lives (whichever is longer) prior to the first dose of study medicine.
• Subject agreed not to intake non-prescription drugs (OTC) within 14 days prior to first dose of study medicine.
• Subject agreed to discontinue vitamins ,dietary and herbal supplements within 14 days prior to the first dose of study medication.
• Subject agreed not to consume grapefruit and/or its products within 14 days prior to the start of study.

You may not qualify if:

• Inability to take oral medication.
• Tested positive for COVID-19 (through COVID-19 antibody testing).
• History of smoking (≤3cigarette/day), alcoholism, and positive test for drug of abuse, heavy pan or gutka user as judged by teeth / mouth inspection.
• Subjects with clinically relevant evidence of cardiovascular, gastrointestinal/hepatic, renal, psychiatric, respiratory, urogenital, hematologic/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, drug hypersensitivity, allergy, endocrine, major surgery or other relevant diseases as revealed by medical history, physical examination, and laboratory assessments which may interfere with the absorption, distribution, metabolism or elimination of drugs or constitute a risk factor when taking study medication.
• Subject is allergic to Lamotrigine and any of the product of lamotrigine .
• Subject has received any investigational drug within four weeks.
• Participated in any clinical trials within 30 days.
• Subjects with salt imbalance in the blood (especially low levels of potassium or magnesium in the blood).
• Donation or loss of more than 450 mL of blood within 3 months prior to the screening.
• History of any significant illness in the last four weeks which might confound in the result of the study or post additional risk in administrating lamotrigine to the subject.
• Concomitant treatment with Valproate, Carbamazepine, phenytoin, phenobarbital, primidone,, rifampin, Estrogen-containing oral contraceptives, Protease inhibitors lopinavir/ritonavir and atazanavir/lopinavir.
• Subjects who test positive for syphilis (VDRL) or who are known to have serum hepatitis or who are carriers of the Hepatitis B surface antigen (HBs Ag) or are carriers of antibodies to hepatitis C virus (anti-HCV) or to the human immunodeficiency virus (HIV-1 or HIV-2).
• Individuals having undergone any major surgery within 3 months prior to the start of the study, unless deemed eligible, otherwise by the Principal Investigator or whomever he/she may designate.
• Subjects with any condition, which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or elimination of drugs.
• History of sensitivity to heparin or heparin-induced thrombocytopenia.

Sponsors & Collaborators

• University of Karachi: lead
• The Searle Company LTD., Pakistan.: collaborator

Study Sites (1)

Center for Bioequivalence Studies and clinical research

Karachi, Sindh, 75270, Pakistan

Location

MeSH Terms

Interventions

Lamotrigine

Intervention Hierarchy (Ancestors)

Triazines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Officials

• Prof. Dr. Muhammad R Shah, PhD

  Center for bio-equivalence studies and clinical research, ICCBS, University of Karachi

  PRINCIPAL INVESTIGATOR

• Dr. Naghma Hashmi (Co-PI), PhD

  Center for bio-equivalence studies and clinical research, ICCBS, University of Karachi

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Model Details: open label, randomized, single-dose, 2 way cross-over study

Study Record Dates

• First Submitted: June 12, 2021
• First Posted: June 24, 2021
• Study Start: September 4, 2020
• Primary Completion: September 24, 2020
• Study Completion: October 25, 2020
• Last Updated: September 8, 2022

Record last verified: 2022-09

Data Sharing

• IPD Sharing: Will share

Locations

PA (1)